The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus
Abstract
Summary: Diabetes mellitus and depressive disorders are both common chronic diseases that increase functional disability and social burden. Cognitive impairment is a potentially debilitating feature of depression. Previous evidence indicates that the antidiabetic drug metformin could be suitable for diabetic patients with cognitive impairment. However, there is no direct evidence from clinical studies that metformin treatment improves cognitive function in diabetic patients suffering from depression. In the present study, 58 participants diagnosed with depression and type 2 diabetes mellitus ( T 2 DM ) were recruited and divided into two groups, one treated with metformin and the other treated with placebo for 24 weeks. Cognitive function, depressive behaviour and diabetes improvement were evaluated. Chronic treatment with metformin for 24 weeks improved cognitive performance, as assessed by the W echsler M emory S cale– R evised, in depressed patients with T 2 DM . In addition, metformin significantly improved depressive performance and changed the glucose metabolism in depressed patients with diabetes. Depressive symptoms were negatively correlated with cognitive performance in metformin‐treated participants. Furthermore, associations were observed between the parameters of blood glucose metabolism and the depression phenotype. These findings suggest that chronic treatment with metformin has antidepressant behavioural effects and that improved cognitive function is involved in the therapeutic outcome of metformin. The results of the present study also raise the possibility that supplementary administration of antidiabetic medications may enhance the recovery of depression, comorbid with T 2 DM , through improvements in cognitive performance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In one small clinical trial, T2DM patients with depression (n = 58) were treated with metformin or placebo for 24 weeks (Guo et al., 2014). The metformin group showed improved cognitive performance and reduced depressive symptoms, concurrent with improved glycemic control.”
From Metformin as a tool to target aging (2016) · cites this paper as Guo et al., 2014
In the citing paper
“The effect of metformin was superior to that of placebo in improving depressive symptoms in a sample of depressive patients with type II diabetes mellitus [122].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [122]
In the citing paper
“In addition, metformin improved memory performance (assessed by the Wechsler Memory Scale-Revised), which was significantly related to a decrease in depressive symptoms [122].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [122]
In the citing paper
“In another clinical trial, 58 participants who had both depression and T2DM received either metformin or placebo for 24 weeks concluded that metformin improved cognitive performance (257).”
From A Critical Review of the Evidence That Metformin Is a Putative Anti-Aging Drug That Enhances Healthspan and Extends Lifespan (2021) · cites this paper as [257]
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Merikangas, K. R., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.593 · Cited by 20,391
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Association of depression and diabetes complications: a meta-analysis
de Groot, M., Anderson, R., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200107000-00015 · Cited by 1,799
Bora, E., Yücel, M., & Pantelis, C. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.06.009 · Cited by 1,058
Mechanism by which metformin reduces glucose production in type 2 diabetes.
Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2063 · Cited by 1,052
Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment
Warner‐Schmidt, J. L., & Duman, R. S. (2006) · Hippocampus · doi:10.1002/hipo.20156 · Cited by 787
Goetzel, R. Z., Hawkins, K., Ozminkowski, R. J., & Wang, S. S. (2003) · Journal of Occupational and Environmental Medicine · doi:10.1097/00043764-200301000-00007 · Cited by 694
Schmidt, H. D., & Duman, R. S. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282ee2aa8 · Cited by 662
Depression and Risk for Onset of Type II Diabetes: A prospective population-based study
Eaton, W. W., Armenian, H. K., Gallo, J. J., Pratt, L., & Ford, D. E. (1996) · Diabetes Care · doi:10.2337/diacare.19.10.1097 · Cited by 611
Strine, T. W., Mokdad, A. H., Dube, S. R., Balluz, L. S., Gonzalez, O., Berry, J. T., Manderscheid, R., & Kroenke, K. (2008) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2007.12.008 · Cited by 577
Research works printed but not linked: 2
- American Psychiatric Association, 2000, Diagnostic and Statistical Manual of Mental Disorders–Fourth Edition
- Wechsler D, 1987, Wechsler Memory Scale‐Revised Manual
Cited by
Sorted by citations
The burden and risks of emerging complications of diabetes mellitus
Tomic, D., Shaw, J. E., & Magliano, D. J. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00690-7 · Cited by 1,377
Metformin as a tool to target aging
Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.011 · Cited by 1,096
Metformin and Its Benefits for Various Diseases
Lv, Z., & Guo, Y. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00191 · Cited by 563
Metformin: a review of its potential indications
Wang, Y., He, S., Feng, X., Cheng, J. Q., Luo, Y.-T., Tian, L., & Huang, Q. (2017) · Drug Design Development and Therapy · doi:10.2147/dddt.s141675 · Cited by 330
Campbell, J. M., Stephenson, M. D., de Courten, B., Chapman, I., Bellman, S. M., & Aromataris, E. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180263 · Cited by 292
Metadata
- Authors
- Guo, M., Mi, J., Jiang, Q., Xu, J., Tang, Y., Tian, G., & Wang, B.
- Affiliations
- Harbin Medical University (CN)
- Binzhou Medical University (CN)
- Division of Endocrinology Aerospace Center Hospital Aerospace Clinical Medical College Peking University Beijing China
- Department of Endocrinology Fourth Affiliated Hospital of Harbin Medical University Harbin China
- Corresponding author
- Guo, Min
- Venue
- Clinical and Experimental Pharmacology and Physiology
- Publisher
- Wiley
- Published
- 2014-09
- Volume
- 41
- Issue
- 9
- Pages
- 650-656
- ISSN
- 0305-1870 (ISSN-L)
- 1440-1681
- OpenAlex
- W2069494503
- Cited by
- 225
- References
- 46
- Citations by year
- 2026: 7 · 2025: 16 · 2024: 9 · 2023: 27 · 2022: 30 · 2021: 28 · 2020: 34 · 2019: 21 · 2018: 22 · 2017: 17 · 2016: 8 · 2015: 6
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical and Experimental Pharmacology and Physiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Peking University
- Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, antidepressant effects, depression, type 2 diabetes, cognitive impairment, cognitive function, glucose metabolism, depressive symptoms, comorbidities, antidiabetic drugs
- MeSH terms
- Adult, Antidepressive Agents, Cognition, Depression, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Psychiatric Status Rating Scales, Wechsler Scales
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
